TIANJIN DEV (00882): Tianjin Lisheng Pharmaceutical expects a net profit of 400 million to 440 million yuan for the year 2025, representing a year-on-year growth of 116.77% to 138.44%.

TIANJIN DEV (00882) announced that it is expected that in the fiscal year 2025, the company's indirectly non-wholly owned subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd. (Tianjin Lisheng Pharmaceutical), will achieve a net profit attributable to the shareholders of the listed company of 4 billion to 4.4 billion yuan. In the same period of the previous year, the profit was 1.85 billion yuan, an increase of 116.77% to 138.44% compared to the same period of the previous year; the net profit after deducting non-recurring gains and losses in the period is 1.6 billion to 1.9 billion yuan, up from 1.03 billion yuan in the same period of the previous year, an increase of 55.34% to 84.47% compared to the same period of the previous year; basic earnings per share are 1.50 yuan/share to 1.80 yuan/share. During the reporting period, the company continued to increase its market expansion efforts, and product sales have improved; in addition, the dividend factor from Tasly Pharmaceutical Group Biopharmaceutical Industry Group Co., Ltd. has had a significant impact on the increase in net profit attributable to the shareholders of the listed company compared to the same period last year.